(0.20%) 5 142.00 points
(0.17%) 38 508 points
(0.27%) 17 894 points
(-0.31%) $83.59
(1.98%) $1.961
(0.10%) $2 349.50
(0.49%) $27.67
(1.05%) $931.80
(-0.06%) $0.934
(-0.14%) $11.01
(-0.19%) $0.799
(1.45%) $93.20
@ $9.53
发出时间: 13 Feb 2024 @ 01:36
回报率: -36.20%
上一信号: Feb 9 - 04:49
上一信号:
回报率: -9.50 %
Live Chart Being Loaded With Signals
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer...
Stats | |
---|---|
今日成交量 | 178 454 |
平均成交量 | 127 423 |
市值 | 268.97M |
EPS | $0 ( 2024-02-13 ) |
下一个收益日期 | ( $-0.190 ) 2024-05-14 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -10.31 |
ATR14 | $0.0430 (0.71%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-24 | Glickman Richard M | Buy | 3 750 | Common Shares |
2024-04-24 | Glickman Richard M | Sell | 3 750 | Options |
2024-04-05 | Virsik Peter | Sell | 694 | Common Shares |
2024-03-25 | Zweifach Sanford S | Buy | 50 000 | Options |
2024-03-25 | Thorell Marella | Buy | 50 000 | Options |
INSIDER POWER |
---|
74.70 |
Last 100 transactions |
Buy: 6 897 304 | Sell: 769 682 |
音量 相关性
ESSA Pharma Inc 相关性
10 最正相关 | |
---|---|
GOODM | 0.808 |
10 最负相关 |
---|
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
ESSA Pharma Inc 相关性 - 货币/商品
ESSA Pharma Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $-118 491 (0.00 %) |
EPS: | $-0.600 |
FY | 2023 |
营收: | $0 |
毛利润: | $-118 491 (0.00 %) |
EPS: | $-0.600 |
FY | 2022 |
营收: | $0 |
毛利润: | $-121 787 (0.00 %) |
EPS: | $-0.800 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-0.960 |
Financial Reports:
No articles found.
ESSA Pharma Inc
ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses on developing novel and proprietary therapies for the treatment of prostate cancer. It develops EPI-7386, an oral candidate that is in a Phase I clinical study for the treatment of patients with metastatic castration-resistant prostate cancer. The company has collaboration agreements with Caris Life Sciences, Inc.; Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。